The closing price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) was $1.85 for the day, down -3.14% from the previous closing price of $1.91. On the day, 1773585 shares were traded.
Ratios:
Our analysis of XERS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.23 and its Current Ratio is at 1.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.
On October 21, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $4.Jefferies initiated its Buy rating on October 21, 2022, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 14 ’24 when Schmid John P. bought 4,500 shares for $2.16 per share. The transaction valued at 9,720 led to the insider holds 11,000 shares of the business.
SHERMAN JEFFREY W bought 5,400 shares of XERS for $10,098 on Nov 27 ’23. The Director now owns 5,400 shares after completing the transaction at $1.87 per share. On Nov 20 ’23, another insider, Pieper Steven, who serves as the insider of the company, bought 28,000 shares for $1.95 each. As a result, the insider paid 54,600 and bolstered with 1,176,912 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $3.26, while it has fallen to a 52-week low of $1.46.
Shares Statistics:
A total of 138.13M shares are outstanding, with a floating share count of 125.56M. Insiders hold about 10.60% of the company’s shares, while institutions hold 41.15% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by VERS analysts. The consensus estimate for the next quarter is $1.73, with high estimates of $0.02 and low estimates of $1.85.
Analysts are recommending an EPS of between $Industrials and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
